NMRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Neumora Therapeutics Inc (NMRA) is not a strong buy for a beginner long-term investor at this time. While there are some positive developments, such as the analyst upgrade and hedge fund buying, the lack of significant financial growth, absence of strong trading signals, and mixed technical indicators suggest that holding off on a purchase is prudent.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 55.681, and moving averages are converging, showing no clear trend. The stock is trading near its pivot point of 2.186, with resistance at 2.377 and support at 1.995.
Analyst upgrade with a price target of $7.62 per share and positive Phase Ib study results for NMRA-511 in Alzheimer's disease agitation.
Hedge fund buying has increased significantly by 327.95% over the last quarter.
No significant insider trading activity or recent congress trading data.
Financials show no revenue growth and a net income loss of -$59.45M in Q4
No recent news or event-driven catalysts.
In Q4 2025, revenue remained at $0 with no YoY growth. Net income improved slightly by 1.07% YoY but remains negative at -$59.45M. EPS dropped by -5.41% YoY to -0.35, and gross margin remains at 0%.
William Blair upgraded the stock to Outperform with a net present value estimate of $7.62 per share, citing positive Phase Ib study results for NMRA-511 in Alzheimer's disease agitation. The analyst views this as a blockbuster market opportunity.
